Clinical TrialsAmadeo2025-01-31T10:29:05+00:00 Clinical Trials Use of streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomized double-blind study. Bertuccioli et al.2023 Preliminary data revealing efficacy of Streptococcus salivarius K12 in periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: A multicenter study from the AIDA network PFAPA syndrome registry. La torre et al.2023 Clinical effects of Streptococcus salivarius K12 in hospitalized COVID-19 patients: Results of a preliminary study. Di Pierro et al.2022 Possibilities of probiotic therapy in chronic inflammatory diseases of oropharynx. Ovchinnikov.2022 The effect of oral probiotics (streptococcus salivarius K12) on the salivary level of secretory immunoglobulin A, salivation rate, and oral biofilm: a pilot randomized clinical trial. Babina et al.2022 Oropharyngeal probiotic ENT-K12 as an effective dietary intervention for children with recurrent respiratory tract infections during cold season. Guo et al.2022 Ways to optimize the treatment of children with diseases of the respiratory tract and ENT organs. Kryuchko and Tkachenko, et al.2021 The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection. Di Pierro et al.2021 Oropharyngeal probiotic ENT-K12 prevents respiratory tract infections among frontline medical staff fighting against COVID-19: A pilot study. Wang et al.2021 Experience with the use of oral probiotic streptococcus salivarius K12 for the prevention of recurrence of pharyngotonsillar episodes. Puhlik et al.2021 « Previous Page1 Page2 Page3 Page4 Next » Year All 2004 2005 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 All 2004 2005 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Health Area Respiratory health Respiratory health
Use of streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomized double-blind study. Bertuccioli et al.2023
Preliminary data revealing efficacy of Streptococcus salivarius K12 in periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: A multicenter study from the AIDA network PFAPA syndrome registry. La torre et al.2023
Clinical effects of Streptococcus salivarius K12 in hospitalized COVID-19 patients: Results of a preliminary study. Di Pierro et al.2022
The effect of oral probiotics (streptococcus salivarius K12) on the salivary level of secretory immunoglobulin A, salivation rate, and oral biofilm: a pilot randomized clinical trial. Babina et al.2022
Oropharyngeal probiotic ENT-K12 as an effective dietary intervention for children with recurrent respiratory tract infections during cold season. Guo et al.2022
Ways to optimize the treatment of children with diseases of the respiratory tract and ENT organs. Kryuchko and Tkachenko, et al.2021
The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection. Di Pierro et al.2021
Oropharyngeal probiotic ENT-K12 prevents respiratory tract infections among frontline medical staff fighting against COVID-19: A pilot study. Wang et al.2021
Experience with the use of oral probiotic streptococcus salivarius K12 for the prevention of recurrence of pharyngotonsillar episodes. Puhlik et al.2021
